60 Degrees Pharmaceuticals, Inc.

SXTP

US83006G1040

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Companyâs products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years of age and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.

Sector

Pharmaceuticals

Calendar

2024-07-15 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for 60 Degrees Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.2249 USD

Average target price

1.3 USD

Spread / Average Target

+478.03%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
60 DEGREES PHARMACEUTICALS, INC.	-77.95%	2.66M
ELI LILLY AND COMPANY	+32.09%	693B
NOVO NORDISK A/S	+29.39%	584B
JOHNSON & JOHNSON	-1.34%	372B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+7.39%	294B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	211B
NOVARTIS AG	+10.02%	210B
AMGEN INC.	+8.49%	168B

Other Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
0.2249 ^USD	+0.85%		-0.04%	-77.95%

May. 02	60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required	CI
Apr. 01	60 Degrees Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required	May. 02	CI
60 Degrees Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024	Mar. 14	CI
60 Degrees Pharmaceuticals, Inc. Appoints Kristen Landon as Chief Commercial Officer	Feb. 08	CI
60 Degrees Pharmaceuticals Closes $2.4 Million Public Offering	Jan. 31	MT
Top Midday Decliners	Jan. 30	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	Jan. 22	MT
60 Degrees Pharmaceuticals Planning Study of Tick-Borne Disease With Malaria Drug; Shares Jump	Jan. 22	MT
60 Degrees Pharma Shares Rise 18% After Type C Meeting With FDA	Jan. 22	DJ
60 Degrees Pharma Plans Tafenoquine Study After FDA Meeting	Jan. 22	DJ
60 Degrees Pharmaceuticals, Inc. Plans Pivotal Babesiosis Study with Tafenoquine	Jan. 22	CI
Certain Warrants of 60 Degrees Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-JAN-2024.	Jan. 12	CI
Certain Common Stock of 60 Degrees Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-JAN-2024.	Jan. 12	CI
60 Degrees Pharmaceuticals, Inc. Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease	Dec. 26	CI
60 Degrees Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 20	CI
60 Degrees Pharmaceuticals, Inc. Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease	Nov. 15	CI
Top Premarket Gainers	23-10-23	MT
Correction: 60 Degrees Pharmaceuticals Subsidiary Suspends Study of Tafenoquine for Mild-to-Moderate COVID-19	23-10-13	MT
60 Degrees Pharmaceuticals Subsidiary Suspends Study of Tafenoquine For Mild-to-Moderate COVID-19	23-10-12	MT
60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne Diseases	23-10-12	CI
Ascendiant Capital Starts 60 Degrees Pharmaceuticals at Buy With $2.40 Price Target	23-10-02	MT
Wall Street Set to Open Marginally Lower as Fed Kicks Off September Policy Meeting	23-09-19	MT
North American Morning Briefing : Stock Futures Lack Momentum as Fed Decision Looms	23-09-19	DJ
60 Degrees Pharma withdraws mid-stage study application for COVID drug	23-09-18	RE
60 Degrees Withdraws COVID Phase IIB Investigational New Drug Application; Shares Drop After-Hours	23-09-18	MT